

## **Gemphire Therapeutics to Present at the Piper Jaffray Healthcare and LD Micro Main Event Conferences**

November 17, 2016 4:01 PM ET

LIVONIA, Mich., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH, today announced that Mina Sooch, President and Chief Executive Officer, will present corporate updates at the Piper Jaffray 28<sup>th</sup> Annual Healthcare Conference and the LD Micro Main Event conference. Gemphire's product candidate, gemcabene, is a novel, once-daily, oral therapy with three separate Phase 2b clinical trials in dyslipidemic patients with HoFH, HeFH/ASCVD and SHTG, scheduled to be completed in 2017.

### **Piper Jaffray Healthcare Conference Presentation Details:**

Date: Tuesday, November 29  
Time: 1:30pm Eastern Time  
Location: The Lotte New York Palace Hotel, Kennedy 1, 4<sup>th</sup> Floor, New York, NY

### **LD Micro Main Event Presentation Details:**

Date: Wednesday, December 7  
Time: 8:30am Pacific Time  
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA

The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire's website at <http://ir.gemphire.com>.

### **About Gemcabene**

Gemphire's product candidate, gemcabene (CI-1027), is a novel, once-daily, oral therapy that may be suitable for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statins. Gemcabene's mechanism of action is designed to enhance the clearance of very low-density lipoproteins (VLDLs) in the plasma and inhibit the production of cholesterol and triglycerides in the liver. The combined effect for these mechanisms has been observed to result in a reduction of plasma VLDL-C, LDL-C, and triglycerides, as well as markedly lowering C-reactive protein. Gemcabene is liver-directed and reduces apoC-III mRNA and plasma levels and may also inhibit acetyl-CoA carboxylase (ACC) which has applications in NASH/NAFLD. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895 subjects across 18 Phase 1 and Phase 2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability.

### **About Gemphire**

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit [www.gemphire.com](http://www.gemphire.com) for more information.

### ***Forward Looking Statements***

Any statements in this press release about Gemphire's future expectations, plans and prospects, including statements about Gemphire's financial prospects, future operations and sufficiency of funds for future operations, clinical development of Gemphire's product candidate, expectations regarding future clinical trials and future expectations and plans and prospects for Gemphire and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," "scheduled" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the success and timing of Gemphire's regulatory

submissions and pre-clinical and clinical trials; regulatory developments; changes to Gemphire's clinical trial designs and regulatory pathways; changes in Gemphire's capital resource requirements; Gemphire's ability to obtain additional financing; Gemphire's ability to successfully market and distribute its product candidate, if approved; Gemphire's ability to obtain and maintain its intellectual property protection; and other factors discussed in the "Risk Factors" section of Gemphire's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016, and in other filings Gemphire makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Gemphire's views as of the date hereof. Gemphire anticipates that subsequent events and developments will cause Gemphire's views to change. However, while Gemphire may elect to update these forward-looking statements at some point in the future, Gemphire specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Gemphire's views as of any date subsequent to the date hereof.

Contact:

Andrew McDonald, Ph.D.  
LifeSci Advisors, LLC  
(646) 597-6987

Jeff Mathiesen, CFO  
Gemphire Therapeutics  
(734)-245-1700



Gemphire Therapeutics